Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC

BACKGROUND: We evaluated the cumulative incidence rate (CIR) of central nervous system (CNS) and non-CNS progression in alectinib-treated patients with anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) to determine the extent to which alectinib may treat or control CNS dis...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Br J Cancer
Asıl Yazarlar: Gadgeel, Shirish, Shaw, Alice T, Barlesi, Fabrice, Crinò, Lucio, Yang, James Chih-Hsin, Dingemans, Anne-Marie C, Kim, Dong-Wan, de Marinis, Filippo, Schulz, Mathias, Liu, Shiyao, Gupta, Ravindra, Kotb, Ahmed, Ou, Sai-Hong Ignatius
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group 2018
Konular:
Clinical Study
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5765233/
https://ncbi.nlm.nih.gov/pubmed/29149104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.395
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller